Ligand Pharmaceuticals IncLGND

Ligand Pharmaceuticals spent $739 million in cash to buy XOMA Royalty and now owns more than 200 royalty assets, including Roche’s VABYSMO, Servier’s OJEMDA, and Zevra’s MIPLYFFA. The deal closed on schedule and adds commercial products that promise long-term growth, yet the company’s own revenue for the quarter was a modest $51.7 million - a figure that would not cover a single major drug launch’s marketing budget. Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand’s business model is simple: collect royalties on drugs it did not invent. The company’s royalty portfolio now spans more than 200 assets, with more than 40 marketed products and a pipeline that includes late-stage programmes across infectious disease, oncology, and rare diseases. The platform relies on Captisol, a solubility enhancer used in roughly 40% of small-molecule drugs, and a handful of high-profile partnerships with global pharma. The company’s website presents this as a sleek, scalable machine, but the balance sheet suggests a quieter reality. Royalty Portfolio - Ligand Pharmaceuticals; Technology Platforms - Ligand Pharmaceuticals

According to the latest 10-Q for the quarter ended 31 March 2026, Ligand reported revenue of $51.7 million, operating income of $17.4 million, and a net loss of $-13.3 million. Diluted EPS was $-0.67 on 19.9 million shares. Cash and cash equivalents stood at $115.1 million, with short-term investments of $664.3 million. Operating cash flow was $48.7 million, while capex was a trivial $228,000. Inventories rose by $4.1 million to $13.3 million. The company’s stockholders’ equity was $997.3 million, and total liabilities were $534.8 million. Research and development spend was $2.1 million. 10-Q, period ending 2026-03-31

The company’s market story pivots on Travere’s FDA approval for FILSPARI (sparsentan) in FSGS, a rare kidney disorder. Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI. Travere’s press release calls it the first and only approved medicine for FSGS, a claim that bolsters the commercial case for the royalty stream. Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

The company’s operating model relies on collecting small slices of revenue from a large number of drugs, which smooths the bumps but also dilutes the upside. Ligand’s 10-Q shows a cash-rich balance sheet with heavy exposure to short-term instruments, while the operating business generates modest revenue and negative net income. The board’s decision to file a 600,000-share S-8 shelf at a time when the stock was not yet registered for resale raises questions about capital allocation priorities. The company’s own filings do not yet demonstrate that the royalty engine can outgrow its cash-gathering role. LGND S-8 (2026-07-22)

For now, Ligand’s equity story is a bet on the scalability of its royalty portfolio and the durability of its Captisol platform. The XOMA acquisition expands the royalty base, but the company’s reported revenue and net income suggest the portfolio has yet to materially shift the income statement. The next catalyst is the commercial performance of the newly acquired assets and the trajectory of royalties on Travere’s FILSPARI. Until then, the stock trades on promise, not profit, and the board’s blank-cheque theatre.